STOCK TITAN

Evoke Pharma Inc - EVOK STOCK NEWS

Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.

Company Overview

Evoke Pharma Inc is a biotechnology and specialty pharmaceutical company strategically located at 505 Lomas Santa Fe Dr, Solana Beach, California. The company is dedicated to advancing therapies in the treatment of gastrointestinal disorders, with a primary focus on addressing the challenges of diabetic gastroparesis. By harnessing innovative nasal drug delivery technology, Evoke Pharma has developed a unique formulation of metoclopramide in its proprietary product, GIMOTI, which is designed to overcome the limitations of traditional oral medications.

Core Business and Product Innovation

Evoke Pharma has positioned itself in the competitive healthcare and biotechnology sectors by developing GIMOTI, an investigational metoclopramide nasal spray. This product offers a novel approach for patients suffering from acute and recurrent diabetic gastroparesis by delivering the active molecule systemically through the nasal mucosa. This method addresses a fundamental issue in the treatment of gastroparesis: the delayed gastric emptying that often impedes the effective absorption of orally administered drugs.

Key industry-specific benefits of this approach include:

  • Nasal Drug Delivery: Eliminates dependence on gastrointestinal absorption, ensuring that patients receive effective and timely relief.
  • Non-Oral Administration: Particularly meaningful in diabetic gastroparesis where conventional oral therapies may not be optimal.
  • Enhanced Patient Outcomes: The innovative formulation has demonstrated potential in reducing healthcare resource utilization, including lower emergency room visits and hospitalizations.

Market Position and Strategic Partnerships

Evoke Pharma is recognized for its specialized focus on GI disorders. It has established a robust market position through strategic collaborations with pharmacy networks and commercial service providers. For instance, its recent transition to a streamlined distribution partner underscores the company’s commitment to improving prescription fill rates and ensuring that GIMOTI is readily accessible to healthcare providers and patients alike.

The company’s strategic initiatives include:

  • Pharmacy Distribution Enhancement: Collaborations with partners such as ASPN Pharmacies and regional pharmacy networks improve coverage and reimbursements, ensuring patients receive their medications promptly.
  • Operational Efficiency: Leadership enhancements and lean business models aid in streamlining operations and reducing overhead costs.
  • Capital and Strategic Developments: Recent capital infusions via warrant exercises have reinforced the company’s balance sheet and supported ongoing commercial growth.

Expertise in Gastrointestinal Therapeutics

At the core of Evoke Pharma's mission is its commitment to addressing the unmet needs within the gastrointestinal healthcare landscape. With GIMOTI, the company focuses on alleviating the symptomatic burden of diabetic gastroparesis—a condition that significantly impairs patient quality of life. By providing an alternative to oral metoclopramide, which can be compromised by delayed gastric emptying, Evoke Pharma’s innovative approach demonstrates a deep understanding of the pathophysiology of the disease and the challenges faced by both patients and healthcare providers.

This focus is augmented by a strategic emphasis on building evidence and partnerships that reinforce the clinical and economic benefits of GIMOTI. The company leverages real-world clinical data and feedback from healthcare professionals to continually refine its therapeutic approach, ensuring that its product not only meets regulatory standards but also provides tangible benefits in reducing hospitalizations and improving patient adherence.

Competitive Landscape and Industry Differentiation

Within the biotechnology and specialty pharmaceuticals sectors, Evoke Pharma distinguishes itself as a pioneer in the non-oral treatment of gastroparesis. Unlike traditional therapies that rely on oral formulations, GIMOTI's intranasal delivery system provides a clinically validated solution to overcome the limitations imposed by compromised gastrointestinal function. This distinct mode of action, supported by real-world data, positions the company as a critical player in a market where effective symptom management can lead to reduced overall healthcare costs.

By focusing on a niche yet significant patient population and establishing a strong network of pharmacy partnerships, Evoke Pharma not only underscores its innovative approach but also builds a sustainable competitive advantage in the evolving pharmaceutical landscape.

Commitment to Quality and Regulatory Excellence

Evoke Pharma maintains an unwavering commitment to quality, regulatory compliance, and clinical excellence. Its product development process is underpinned by rigorous research, strategic operational enhancements, and adherence to established industry standards. As the sole developer of a nasal spray formulation of metoclopramide approved for the treatment of diabetic gastroparesis, the company continues to invest in initiatives that bolster its intellectual property portfolio and broaden its market access.

In summary, Evoke Pharma Inc represents a well-positioned entity in the biotechnology and specialty pharmaceutical industries. With its innovative GIMOTI product, the company addresses a critical gap in gastroparesis treatment through a novel, non-oral delivery system. Its strategic partnerships, focus on operational efficiency, and commitment to enhancing patient outcomes cement its role as an authoritative source of innovation in gastrointestinal therapeutics.

Investor and Healthcare Provider Insights

For investors and healthcare professionals seeking to understand the dynamics of the GI therapeutic landscape, Evoke Pharma offers an exemplary case study of targeted innovation. By leveraging its unique product formulation and strategic market initiatives, the company not only meets an urgent medical need but also reinforces its position within a competitive and rapidly evolving sector.

Rhea-AI Summary
Evoke Pharma, Inc. announces the appointment of Matthew J. D’Onofrio as the new CEO, succeeding David A. Gonyer. The company remains focused on GIMOTI® nasal spray for GI diseases. Mr. D’Onofrio expresses commitment to the core mission of expanding GIMOTI's reach to more patients. The board shows confidence in his leadership and vision for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
management
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) reported a significant 107% increase in net product sales for fiscal year 2023, totaling $5.2M, with projected net revenue of $14M for 2024. The company focused on expanding market share for GIMOTI nasal spray, resulting in a rise in prescribers, prescription fills, and patient enrollments. Recent developments include reduced healthcare resource utilization with GIMOTI, transition to ASPN Pharmacies for enhanced prescription processes, strengthened patent estate, and improved cash position through a $7.5M public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.15%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) is set to release its fourth quarter and full year 2023 financial results on March 14, 2024. The company will host a conference call to discuss the results, focusing on their specialty pharmaceutical products for GI diseases, particularly Gimoti® nasal spray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) closes a $30 million public offering led by Nantahala Capital Management, with potential for an additional $22.5 million if all warrants are exercised. The company plans to use the funds for working capital, general corporate purposes, and potentially for in-licensing, acquiring, or investing in complementary businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced an underwritten public offering led by Nantahala Capital Management, raising up to $30 million for working capital and corporate purposes. The offering includes 11,029,411 shares of common stock and warrants, with a combined price per share of $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.86%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced that its GIMOTI nasal spray has received a new U.S. patent, No. 11,813,231, listed in the FDA's Orange Book, with coverage until 2029. This adds to the previous three patents, providing enhanced patent protection for GIMOTI. The company aims to redefine gastroparesis treatment with GIMOTI, targeting diabetic gastroparesis and reducing hospitalizations. The patent listing in the Orange Book allows for easier monitoring of potential generic drugs that could infringe on GIMOTI's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide” for their commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI. This patent provides additional intellectual property protections and claims to metoclopramide being delivered intranasally. The company sees significant commercial value, especially with the rising popularity of GLP-1 agonist medications for diabetes potentially unmasking gastroparesis in larger patient groups. GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis, addressing the unpredictability of tablet absorption caused by gastroparesis symptoms. Evoke Pharma aims to continue providing patients with life-changing experiences and enhancing the commercial opportunity for GIMOTI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) reports a 38% revenue increase compared to Q2 2023 and an 88% increase year-over-year. The company experienced a seventh straight prescription fill increase since Q1 2022, with a 21% increase compared to Q2 2023 and a 95% increase year-over-year. The financial results for the third quarter ended September 30, 2023, show record net product sales of $1.6 million. The company also presented data at the ACG 2023 Annual Meeting demonstrating the superiority of its nasal spray, GIMOTI, in reducing healthcare costs for treating diabetic gastroparesis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
-
Rhea-AI Summary
Evoke Pharma and EVERSANA announced real-world data on the positive impact of GIMOTI nasal spray in reducing healthcare costs for patients with diabetic gastroparesis. Patients and insurers saved over $15,000 per patient in a six-month period by using GIMOTI instead of oral metoclopramide. The study showed a significant reduction in emergency department visits, hospitalizations, and office visits for patients using GIMOTI compared to oral metoclopramide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Evoke Pharma to present real-world healthcare utilization data on GIMOTI nasal spray at the American College of Gastroenterology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none

FAQ

What is the current stock price of Evoke Pharma (EVOK)?

The current stock price of Evoke Pharma (EVOK) is $2.51 as of April 1, 2025.

What is the market cap of Evoke Pharma (EVOK)?

The market cap of Evoke Pharma (EVOK) is approximately 3.8M.

What is the core focus of Evoke Pharma Inc?

Evoke Pharma Inc specializes in developing innovative therapies for gastrointestinal disorders, with a specific focus on diabetic gastroparesis.

What is GIMOTI and how does it differ from traditional therapies?

GIMOTI is a metoclopramide nasal spray designed for the treatment of diabetic gastroparesis. It bypasses the gastrointestinal tract, offering an alternative to traditional oral medications, especially in patients with compromised drug absorption.

How does Evoke Pharma generate revenue?

Revenue is generated through the commercialization of its specialty pharmaceutical product, GIMOTI, supported by strategic partnerships with pharmacy distributors and commercial service providers.

What makes Evoke Pharma's approach unique in the treatment landscape?

The company uses nasal drug delivery to address the challenges of oral medication absorption in gastroparesis, making GIMOTI the only FDA-approved non-oral treatment available for this condition.

Who are the primary beneficiaries of Evoke Pharma's treatments?

Patients suffering from diabetic gastroparesis and healthcare providers managing gastrointestinal conditions benefit from the innovative, effective, and accessible treatment options developed by the company.

What strategic partnerships support Evoke Pharma's commercial efforts?

Evoke Pharma has established partnerships with pharmacy networks and commercial service providers, including collaborations with ASPN Pharmacies and regional partners, to enhance prescription fill rates and market access.

How does Evoke Pharma ensure product quality and regulatory compliance?

The company adheres to stringent research protocols, regulatory standards, and continuous operational enhancements, which are integral to its product development and commercialization strategies.

How is Evoke Pharma positioned within the competitive pharmaceutical landscape?

Evoke Pharma differentiates itself through its unique nasal delivery technology for metoclopramide, strong clinical evidence, and strategic market initiatives, positioning it as a notable player in the GI therapeutic space.
Evoke Pharma Inc

Nasdaq:EVOK

EVOK Rankings

EVOK Stock Data

3.76M
1.41M
5.02%
14.64%
2.1%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SOLANA BEACH